Ivermectin Prices, Trend 2026: Index, Demand, Chart and Forecast
According to ChemAnalyst, The global market for Ivermectin Prices moved upward during the second quarter of 2026, although the intensity of the increase varied significantly across North America, Asia-Pacific (APAC), and Europe. Higher manufacturing expenses, elevated chemical feedstock costs, energy-price volatility, and changing pharmaceutical supply-chain conditions were the primary factors influencing the market.
Ivermectin is a broad-spectrum antiparasitic pharmaceutical compound used in approved treatments for several parasitic infections in humans and animals. Consequently, its pricing is influenced by pharmaceutical manufacturing activity, raw-material availability, healthcare demand, regulatory conditions, and international trade flows.
During Q2 2026, producers faced a challenging cost environment. In the United States, producer prices increased by 5.5% year-over-year in June, while China's PPI increased by 4.1%. Germany also recorded a 2.2% increase in producer prices for industrial products in May. These developments increased the cost base for pharmaceutical and chemical manufacturers.
At the same time, regional demand conditions differed. North America benefited from relatively resilient economic activity and healthcare spending, while China's slower retail-sales growth limited demand momentum. In Europe, weak consumer confidence and subdued industrial activity restrained purchasing enthusiasm despite rising production costs.
Ivermectin Prices in North America
In the United States, the Ivermectin Price Index increased quarter-over-quarter in Q2 2026, supported by higher production costs and relatively resilient pharmaceutical demand. Manufacturers encountered increased expenses for chemical inputs, utilities, labor, logistics, and compliance-related activities.
A major contributor to the increase was the rise in producer prices. The U.S. PPI increased 5.5% year-over-year in June 2026, indicating continued inflationary pressure across the industrial supply chain. For ivermectin manufacturers, higher prices for intermediate chemicals and supporting materials translated into increased manufacturing costs.
Demand conditions also provided support to the market. U.S. retail sales increased 6.9% year-over-year in May 2026, reflecting relatively healthy consumer spending. Although retail activity does not directly determine pharmaceutical active ingredient consumption, stronger spending conditions can support broader healthcare and medical-product demand.
Consumer inflation remained elevated, with the U.S. CPI increasing 3.5% year-over-year in June 2026. Nevertheless, unemployment remained relatively low at 4.2%, helping sustain household income and purchasing capacity.
Industrial production increased only 0.7% year-over-year in June, suggesting that the broader industrial economy was expanding at a relatively modest pace. This limited the extent to which manufacturing activity could offset rising input costs.
Energy markets presented a mixed picture. Lower natural gas prices at Henry Hub in April provided some relief to industrial producers. However, increasing retail electricity revenues per kilowatt-hour added pressure to manufacturing expenses, particularly for facilities requiring continuous electricity for production, purification, drying, and other processing stages.
New U.S. trade measures also influenced pharmaceutical supply chains during Q2. Manufacturers and distributors increasingly focused on supplier diversification and inventory management to reduce exposure to trade-related disruptions.
Get Real Time Online for Ivermectin Prices: https://www.chemanalyst.com/Pricing-data/ivermectin-1381
Why Did Ivermectin Prices Change in June 2026 in North America?
Several factors contributed to the movement in Ivermectin Prices in North America:
- Higher production costs: U.S. PPI increased 5.5% YoY in June, raising the cost base for pharmaceutical manufacturing.
- Resilient demand: Strong retail activity and healthcare spending supported demand for pharmaceutical products.
- Low unemployment: The 4.2% unemployment rate supported household income and overall purchasing capacity.
- Moderate consumer confidence: Confidence remained sufficient to support economic activity despite inflationary pressures.
- Energy-cost divergence: Lower natural gas prices offered some relief, while electricity costs continued to pressure manufacturers.
- Supply-chain diversification: Changing trade measures encouraged pharmaceutical companies to diversify sourcing and manage inventories more carefully.
Overall, North American ivermectin prices maintained an upward trajectory in Q2 2026 as cost inflation outweighed the relief generated by lower natural gas prices.
Ivermectin Prices in APAC
The Ivermectin Price Index in APAC also increased quarter-over-quarter during Q2 2026, with China remaining an important production and export hub.
In China, the average FOB price of ivermectin was approximately USD 98,000/MT during Q2 2026. The price increase was primarily associated with higher manufacturing costs and rising prices for chemical feedstocks and intermediate raw materials.
China's PPI increased 4.1% year-over-year in June 2026, pointing toward significant producer-side inflation. Pharmaceutical and chemical manufacturers therefore faced increased costs for raw materials, utilities, transportation, and other production inputs.
However, demand conditions were comparatively weaker. Chinese retail sales grew only 1.0% year-over-year in June 2026, indicating subdued consumer spending. This limited the ability of downstream buyers to absorb significant price increases and prevented a stronger upward movement in ivermectin prices.
The manufacturing environment nevertheless remained supportive. China's Manufacturing Index expanded in June, while industrial production grew 5.3% year-over-year. Strong industrial output helped maintain the availability of chemical inputs and supported production capacity.
Chinese chemical exporters also achieved counter-cyclical growth during Q2. Competitive production economics, established manufacturing capacity, and export-oriented supply chains allowed Chinese producers to remain active in international markets despite weaker domestic demand.
Feedstock costs represented another important pricing factor. Ivermectin manufacturing requires multiple chemical intermediates and processing stages, making the product sensitive to fluctuations in upstream chemical prices. Rising raw-material costs therefore translated into higher production expenses even when downstream demand was relatively soft.
Why Did Ivermectin Prices Change in June 2026 in APAC?
The main factors influencing Ivermectin Prices in APAC included:
- 4.1% YoY increase in China's PPI, which increased manufacturing costs.
- Higher feedstock prices, raising the cost of pharmaceutical intermediates.
- Weak retail demand, with retail sales growth limited to 1.0% YoY in June.
- Strong industrial production, which supported chemical supply-chain activity.
- Manufacturing-sector expansion, providing a favorable environment for producers.
- Export competitiveness, allowing Chinese suppliers to maintain international shipments despite slower domestic consumption.
Consequently, China's ivermectin market experienced moderate upward price pressure rather than a sharp increase. Higher production expenses provided the primary support, while weak downstream demand restrained the magnitude of the rise.
Ivermectin Prices in Europe
The European ivermectin market followed a similar cost-driven pattern during Q2 2026, although weaker demand conditions limited price momentum.
In Germany, the Ivermectin Price Index increased quarter-over-quarter, primarily because of sharply rising input costs. Producer prices for industrial products increased 2.2% year-over-year in May 2026, raising expenses for pharmaceutical and chemical manufacturers.
Energy costs remained a particularly important concern. Higher electricity prices increased operating expenses for industrial facilities, while Germany's chemical sector continued to experience challenging external-market conditions.
Domestic demand was also subdued. Consumer confidence declined to -14.6 in June 2026, indicating cautious consumer sentiment. Although retail sales increased 1.8% year-over-year in May, this improvement was not sufficient to generate strong broad-based demand momentum.
German unemployment remained relatively stable at 3.8% in May, providing some stability to household purchasing power. However, weak industrial conditions continued to weigh on business confidence and pharmaceutical procurement.
Germany's industrial production remained unchanged at 0.0% in May, highlighting the lack of significant industrial expansion. Chemical-sector exports also declined during the first half of 2026, adding further pressure to producers operating in internationally competitive markets.
Despite these demand-side constraints, manufacturers continued to face higher energy and chemical-input expenses. The resulting margin pressure encouraged some buyers to build precautionary inventories during Q2. These inventory purchases generated short-term sales increases, but procurement strategies remained conservative, with buyers generally preferring lean inventory levels.
Consumer inflation reached 2.3% year-over-year in June, further increasing the cost environment for the broader economy.
Book A Demo for Ivermectin Prices: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Ivermectin
Why Did Ivermectin Prices Change in June 2026 in Europe?
The primary drivers of Ivermectin Prices in Europe were:
- Industrial producer prices increased 2.2% YoY, raising manufacturing costs.
- High electricity and energy prices increased operating expenses.
- Weak consumer confidence, which reduced demand-side momentum.
- Flat industrial production, reflecting subdued manufacturing activity.
- Lower chemical exports, limiting external demand for German producers.
- Precautionary inventory purchases, providing temporary support to sales.
- Lean inventory strategies, preventing stronger sustained demand.
Therefore, European ivermectin prices increased mainly because of cost inflation rather than strong consumption growth.
Key Factors Influencing Global Ivermectin Prices in Q2 2026
Several common themes shaped the global ivermectin market during the quarter.
Rising Production Costs
Producer-price inflation was one of the most important factors supporting ivermectin prices. Higher costs for chemical intermediates, feedstocks, utilities, packaging, labor, and logistics increased the overall manufacturing cost.
Chemical Feedstock Prices
Ivermectin production is dependent on a network of chemical intermediates. Any increase in upstream chemical prices can raise the cost of active pharmaceutical ingredient production and eventually affect spot and contract pricing.
Energy Costs
Energy remains critical for pharmaceutical manufacturing. Electricity costs were particularly important in Europe and North America, while movements in natural gas prices provided mixed cost signals.
Regional Demand Differences
Demand was stronger in North America than in China and Europe. U.S. healthcare-related demand and resilient consumer activity provided support, whereas China's weak retail growth and Europe's declining consumer confidence limited price gains.
Pharmaceutical Supply-Chain Management
Trade-policy developments encouraged pharmaceutical companies to diversify suppliers, strengthen inventories, and reduce dependence on individual production hubs. These measures can increase short-term procurement costs while improving supply-chain resilience.
Inventory Strategies
Buyers in Europe and other markets adopted cautious procurement strategies. Some companies increased inventories temporarily as a precaution, but many continued to maintain lean stocks to minimize working-capital exposure.
Ivermectin Price Trend Outlook
The outlook for Ivermectin Prices remains moderately firm following the developments observed during Q2 2026.
In North America, continued producer-price inflation and resilient healthcare demand could keep prices elevated. However, softer industrial growth and changes in energy costs may limit further increases.
In China, the outlook will depend heavily on the balance between production costs and downstream demand. Strong industrial production and manufacturing activity can support supply, while weak retail growth may restrict the ability of producers to pass the full increase in raw-material costs to buyers.
European prices are likely to remain under upward cost pressure. Elevated electricity prices and chemical-input costs could continue to challenge manufacturers, although weak consumer confidence and subdued industrial activity may cap demand-driven price growth.
From a procurement perspective, buyers are likely to remain focused on supplier diversification, inventory optimization, and long-term sourcing agreements. Producers with efficient manufacturing processes and secure access to chemical feedstocks may be better positioned to manage margin pressure.
Conclusion
The Ivermectin Prices market experienced a broadly positive price trend in Q2 2026, but regional market dynamics differed considerably. North America recorded upward momentum because of higher production costs and relatively resilient demand. In APAC, particularly China, prices increased as producer inflation and chemical-input costs outweighed weak domestic consumption. Europe also witnessed higher prices, largely because of elevated energy and industrial input costs despite weak demand.
About Us:
Welcome to ChemAnalyst, a next–generation platform for chemical and petrochemical intelligence where innovation meets practical insight. Recognized as “Product Innovator of the Year 2023” and ranked among the “Top 100 Digital Procurement Solutions Companies,” we lead the digital transformation of the global chemical sector. Our online platform helps companies handle price volatility with structured analysis, real-time pricing, and reliable news and deal updates from across the world. Tracking over 500 chemical prices in more than 40 countries becomes simple and efficient with us.
Contact Us:
Address:
420 Lexington Avenue, Suite 300 New York, NY 10170 United States
Phone: +1 332 258 6602
Email: [email protected]
Website: https://www.chemanalyst.com/
LinkedIn: https://www.linkedin.com/company/chemanalyst/
Facebook: https://www.facebook.com/ChemAnalysts/
Twitter: https://x.com/chemanalysts
YouTube: https://www.youtube.com/@chemanalyst
Instagram: https://www.instagram.com/chemanalyst_